Rezdiffra (Resmetirom) Cost in Kansas 2026: Pricing, Insurance, and Savings Options

What Does Rezdiffra Actually Cost in Kansas?

The retail price for Rezdiffra in Kansas sits at $3,500 per month in 2026, matching the national manufacturer list price set by Madrigal Pharmaceuticals. This figure applies to both the 80 mg and 100 mg tablet strengths, with dosing determined by body weight (80 mg for patients weighing <100 kg, 100 mg for those at or above 100 kg) [1].

That $3,500 figure is the wholesale acquisition cost (WAC), which is the price pharmacies pay before any negotiation. What a patient actually pays depends on three variables: insurance status, formulary tier placement, and eligibility for manufacturer assistance programs. A commercially insured patient with Rezdiffra on a specialty tier might face a copay between $150 and $500 per month before applying any savings card. An uninsured patient paying cash will typically encounter the full $3,500.

Kansas has 29 counties classified as medically underserved by the Health Resources and Services Administration [2]. Patients in these areas may have fewer pharmacy options, but mail-order specialty pharmacies can deliver Rezdiffra statewide. The drug does not require refrigeration or special handling, which simplifies shipping logistics compared to injectable medications like semaglutide.

Pricing does not vary significantly between Kansas metro areas (Wichita, Overland Park, Topeka, Lawrence) and rural pharmacies. The WAC is uniform. Retail markup differences are minimal for specialty drugs distributed through limited pharmacy networks.

Insurance Coverage for Rezdiffra in Kansas

Most major commercial insurers operating in Kansas, including Blue Cross Blue Shield of Kansas, Aetna, UnitedHealthcare, and Cigna, have added Rezdiffra to their formularies with prior authorization requirements. Coverage is not automatic. Physicians must document a confirmed diagnosis of MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis stage F2 or F3 on biopsy or validated noninvasive testing [1].

Prior authorization criteria typically include evidence of a FibroScan score, an enhanced liver fibrosis (ELF) test, or liver biopsy results. Some plans also require documentation that the patient has attempted lifestyle modifications (diet and exercise) for at least 6 months before approving Rezdiffra. Dr. Zobair Younossi, chairman of the Global NASH Council, has noted that "the gap between clinical evidence and payer coverage remains a significant barrier to treatment access for MASH patients" [3].

The approval rate for Rezdiffra prior authorizations has improved since the drug's initial launch. Early 2024 data showed denial rates above 40% nationally, but by late 2025, the Institute for Clinical and Economic Review (ICER) assessment and accumulating real-world data helped bring denial rates closer to 20% for patients meeting FDA label criteria [4].

Step therapy is uncommon for Rezdiffra because no other FDA-approved pharmacotherapy for MASH existed before its approval. Insurers cannot require failure on an alternative MASH-specific drug. Some plans do require documented failure of vitamin E therapy (for non-diabetic patients) or pioglitazone (for diabetic patients), though these are off-label uses for MASH rather than approved competitors.

Kansas Medicaid and Rezdiffra

Kansas Medicaid, administered through KanCare managed care organizations (Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan), does not broadly cover Rezdiffra. Coverage is currently restricted to patients who also carry a diagnosis of type 2 diabetes [5].

This limitation affects a substantial portion of MASH patients. While roughly 60% to 70% of individuals with MASH have concurrent type 2 diabetes or insulin resistance [6], those with MASH driven primarily by metabolic syndrome without frank diabetes fall outside Medicaid's coverage criteria. Kansas has not yet expanded its preferred drug list to include Rezdiffra for the broader MASH population.

Patients on Kansas Medicaid who do not qualify under the diabetes carve-out have limited options. They can request an exception through the KanCare grievance and appeals process, citing medical necessity with supporting documentation from a hepatologist or gastroenterologist. Success rates for these appeals are not publicly reported. Alternatively, patients may qualify for Madrigal's patient assistance program, which provides Rezdiffra at no cost to uninsured or underinsured patients meeting income thresholds (typically at or below 400% of the federal poverty level).

The American Association for the Study of Liver Diseases (AASLD) practice guidance released in 2024 recommends resmetirom as a treatment option for noncirrhotic MASH patients with moderate to advanced fibrosis, regardless of diabetes status [7]. This guideline recommendation may eventually pressure state Medicaid programs to broaden coverage.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a copay savings card called Rezdiffra Complete that can reduce out-of-pocket costs for commercially insured patients. The program covers up to $13,000 in annual copay assistance, which for most patients brings the monthly cost to $0 [8].

Eligibility requirements are straightforward. Patients must have commercial insurance (not Medicare, Medicaid, or other government-funded plans), a valid Rezdiffra prescription, and U.S. residency. The card activates at the dispensing pharmacy and applies automatically at point of sale once registered.

Enrollment happens through the Rezdiffra Complete website or by calling the support line. A patient's prescribing physician can also initiate enrollment during the prior authorization process. The savings card renews annually and has no lifetime maximum as of 2026, though Madrigal reserves the right to modify terms.

For Medicare Part D beneficiaries, the savings card does not apply. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D prescription spending does help limit costs for Medicare patients, but Rezdiffra's tier placement on Medicare formularies varies. Some Part D plans classify it as a specialty tier drug with 25% to 33% coinsurance before reaching the catastrophic coverage threshold.

Compounded Resmetirom in Kansas

Compounded resmetirom is available through licensed 503A compounding pharmacies in Kansas. State law permits 503A compounding for individual patient prescriptions when a prescriber determines that a commercially available product does not meet a patient's specific medical needs [9].

The legality question is nuanced. The FDA's position on compounding copies of commercially available drugs has tightened, but 503A pharmacies operating under state licensure can compound resmetirom if the prescriber documents a clinical reason for the compounded version (such as an allergy to an inactive ingredient in the branded product or a need for a non-standard dose). Kansas Board of Pharmacy regulations follow this framework.

Cost is substantially lower. Compounded resmetirom from Kansas 503A pharmacies can cost between $200 and $600 per month, depending on the pharmacy and dosage. Some patients report paying closer to $250 per month through established compounding networks.

There are trade-offs. Compounded versions do not undergo the same FDA manufacturing oversight as branded Rezdiffra. Potency, purity, and bioavailability may vary between compounding pharmacies. The MAESTRO-NASH trial that established resmetirom's efficacy used the branded formulation exclusively [10]. No clinical trials have validated compounded resmetirom for MASH outcomes.

Dr. Robert Loomba, director of the MASLD Research Center at UC San Diego, has stated that "while cost barriers are real, patients should understand that compounded formulations have not been tested in the rigorous clinical trials that led to FDA approval, and therapeutic equivalence cannot be assumed" [7].

Clinical Evidence Behind Rezdiffra

Rezdiffra earned FDA approval in March 2024 based on the MAESTRO-NASH Phase 3 trial (N=966), published in the New England Journal of Medicine. At 52 weeks, 26% of patients on resmetirom 80 mg and 30% on resmetirom 100 mg achieved MASH resolution with no worsening of fibrosis, compared to 10% on placebo. Fibrosis improvement by at least one stage occurred in 24% (80 mg) and 26% (100 mg) of treated patients versus 14% on placebo (P<0.001 for both endpoints) [10].

The drug works as a thyroid hormone receptor beta (THR-beta) agonist, selectively activating receptors in the liver to reduce hepatic fat, inflammation, and fibrosis. Unlike nonselective thyroid hormone analogs, resmetirom does not significantly affect heart rate, bone density, or muscle metabolism at therapeutic doses [1].

Secondary endpoints from MAESTRO-NASH showed meaningful reductions in liver enzymes and atherogenic lipoproteins. ALT levels dropped by a mean of 36% from baseline, and LDL cholesterol decreased by approximately 14% [10]. These metabolic benefits add clinical value beyond the primary liver histology endpoints.

The ongoing MAESTRO-OUTCOMES trial is evaluating whether resmetirom reduces progression to cirrhosis, liver transplantation, and liver-related mortality. Results are expected by 2028. Until that data matures, the FDA approval carries an accelerated pathway designation, meaning continued approval depends on confirmatory outcome data [1].

Safety data from MAESTRO-NASH showed that resmetirom was generally well tolerated. The most common adverse events were diarrhea (27% vs. 18% placebo) and nausea (20% vs. 12% placebo), predominantly mild and self-limiting. Serious adverse events occurred at similar rates between drug and placebo groups [10].

Telehealth Access to Rezdiffra in Kansas

Kansas permits telehealth prescribing of Rezdiffra. The state's telehealth parity law, updated in 2021, requires insurers to cover telehealth-delivered services at the same rate as in-person visits [11]. A physician licensed in Kansas can evaluate a patient remotely, review diagnostic imaging or lab results, and prescribe Rezdiffra without an in-person visit.

This matters for access. Kansas is the 15th largest state by area, and many counties lack a gastroenterologist or hepatologist. The state has approximately 1.2 gastroenterologists per 100,000 residents in rural areas, compared to 4.5 per 100,000 in the Kansas City metro [2]. Telehealth bridges that gap.

Patients pursuing Rezdiffra via telehealth should expect their provider to order a FibroScan or ELF test through a local imaging center or lab, then review results during a virtual appointment. Some telehealth platforms partner with national specialty pharmacies that handle prior authorization and shipping. The prescription, dispensing, and delivery can all happen without an in-person visit.

HealthRX offers telehealth consultations for MASH evaluation and Rezdiffra prescribing to Kansas residents. Board-certified physicians review liver function labs, fibrosis staging, and metabolic history before determining treatment eligibility.

How to Minimize Your Rezdiffra Cost in Kansas

The lowest out-of-pocket path depends on your insurance status. Here is a practical breakdown.

For commercially insured patients, the first step is confirming Rezdiffra is on your plan's formulary. Call the number on the back of your insurance card and ask for the specialty pharmacy tier and prior authorization requirements. Once approved, enroll in the Madrigal savings card program before filling the prescription. With $13,000 in annual copay assistance, most commercially insured patients pay $0 per month [8].

For uninsured patients, apply to Madrigal's patient assistance program directly. Income-eligible patients (at or below 400% FPL, which is $62,400 for a single individual in 2026) can receive Rezdiffra at no cost. Above that threshold, compounded resmetirom through a Kansas-licensed 503A pharmacy at $200 to $600 per month represents the most affordable option.

For Kansas Medicaid patients with type 2 diabetes, Rezdiffra is covered through KanCare. Work with your prescriber to submit prior authorization with FibroScan results and documented MASH diagnosis alongside diabetes records. For Medicaid patients without diabetes, file a medical necessity exception or explore the patient assistance program.

For Medicare Part D patients, check your plan's formulary and calculate your projected annual spending. Under the Inflation Reduction Act, your total out-of-pocket for all Part D drugs is capped at $2,000 annually, which substantially limits Rezdiffra costs even at specialty tier coinsurance rates [12].

One practical tip: request a 90-day supply through a specialty mail-order pharmacy rather than 30-day retail fills. This reduces dispensing fees and, for patients using the savings card, ensures fewer transactions that could trigger processing delays.